Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United States Oil ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.77 (market cap $39.89B), while United States Oil ETF trades at $113.68. The key difference: United States Oil ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | USO | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $152.96 |
52-Week Low | $278.09 | $66.17 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
USO trades at $108.7, down 0.29% today, with a neutral technical signal and bearish moving averages. Recent news highlights oil price volatility driven by geopolitical tensions, including a 7% spike in WTI crude and Russia's diesel export ban. Support and resistance levels are tightly clustered, indicating potential for near-term price movement.
The outlook for USO is influenced by oil market dynamics, with supply risks from Middle East conflicts and strategic reserve buying providing support. However, risks include potential demand declines and geopolitical resolutions that could pressure prices. Investors should weigh these factors against current technical neutrality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
